Medmix Ltd
SIX:MEDX
Intrinsic Value
medmix AG designs, develops and produces delivery devices for the mixing, application and injection of liquids for the healthcare, consumer and industrial end-markets. [ Read More ]
The intrinsic value of one MEDX stock under the Base Case scenario is 29.11 CHF. Compared to the current market price of 14.96 CHF, Medmix Ltd is Undervalued by 49%.
Valuation Backtest
Medmix Ltd
Run backtest to discover the historical profit from buying and selling MEDX stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Medmix Ltd
Current Assets | 340.4m |
Cash & Short-Term Investments | 152.7m |
Receivables | 86.9m |
Other Current Assets | 100.8m |
Non-Current Assets | 631.2m |
Long-Term Investments | 8.4m |
PP&E | 251m |
Intangibles | 363.8m |
Other Non-Current Assets | 8m |
Current Liabilities | 147.6m |
Accounts Payable | 65.7m |
Other Current Liabilities | 81.9m |
Non-Current Liabilities | 337.1m |
Long-Term Debt | 306.6m |
Other Non-Current Liabilities | 30.5m |
Earnings Waterfall
Medmix Ltd
Revenue
|
474.6m
CHF
|
Cost of Revenue
|
-315.1m
CHF
|
Gross Profit
|
159.5m
CHF
|
Operating Expenses
|
-136.4m
CHF
|
Operating Income
|
23.1m
CHF
|
Other Expenses
|
-28m
CHF
|
Net Income
|
-4.9m
CHF
|
Free Cash Flow Analysis
Medmix Ltd
What is Free Cash Flow?
MEDX Profitability Score
Profitability Due Diligence
Medmix Ltd's profitability score is 49/100. The higher the profitability score, the more profitable the company is.
Score
Medmix Ltd's profitability score is 49/100. The higher the profitability score, the more profitable the company is.
MEDX Solvency Score
Solvency Due Diligence
Medmix Ltd's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Score
Medmix Ltd's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MEDX Price Targets Summary
Medmix Ltd
According to Wall Street analysts, the average 1-year price target for MEDX is 30.6 CHF with a low forecast of 30.3 CHF and a high forecast of 31.5 CHF.
Shareholder Return
MEDX Price
Medmix Ltd
Average Annual Return | -28.42% |
Standard Deviation of Annual Returns | 46.17% |
Max Drawdown | -68% |
Market Capitalization | 611.5m CHF |
Shares Outstanding | 40 781 847 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
medmix AG designs, develops and produces delivery devices for the mixing, application and injection of liquids for the healthcare, consumer and industrial end-markets. The company is headquartered in Zug, Zug and currently employs 2,101 full-time employees. The firm operates in business areas such as: the dental segment, which provides MIXPAC and transcodent - system solutions that are used to dose, mix and apply various types of dental materials; drug delivery- solutions for the dosage and application of drugs; a surgical segment which provides devices for bone regeneration and tissue healing; an industry segment that specializes in the mixing and dosing of sealants and adhesives through IXPAC , COX and MK; and a beauty segment in which it produces cosmetic applicators through the GEKA brand.
Officers
The intrinsic value of one MEDX stock under the Base Case scenario is 29.11 CHF.
Compared to the current market price of 14.96 CHF, Medmix Ltd is Undervalued by 49%.